Genetic risk of clozapine-induced leukopenia and neutropenia: a genome-wide association study

[1]  Robert Karlsson,et al.  RICOPILI: Rapid Imputation for COnsortias PIpeLIne , 2019, bioRxiv.

[2]  S. Potkin,et al.  Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. , 2019, The Journal of clinical psychiatry.

[3]  J. Walters,et al.  Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective , 2019, Pharmacogenomics.

[4]  D. Rujescu,et al.  A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia , 2019, Molecular Psychiatry.

[5]  G. Hansmann,et al.  Inhibition of neogenin fosters resolution of inflammation and tissue regeneration , 2018, The Journal of clinical investigation.

[6]  M. Large,et al.  Meta‐analysis examining the epidemiology of clozapine‐associated neutropenia , 2018, Acta psychiatrica Scandinavica.

[7]  Nicole L La Gruta,et al.  Understanding the drivers of MHC restriction of T cell receptors , 2018, Nature Reviews Immunology.

[8]  N. Kanahara,et al.  Transethnic Replication Study to Assess the Association Between Clozapine-Induced Agranulocytosis/Granulocytopenia and Genes at 12p12.2 in a Japanese Population , 2017, Biological Psychiatry.

[9]  Y. Kamatani,et al.  Polygenic burdens on cell-specific pathways underlie the risk of rheumatoid arthritis , 2017, Nature Genetics.

[10]  R. Ophoff,et al.  More than 25 years of genetic studies of clozapine-induced agranulocytosis , 2017, The Pharmacogenomics Journal.

[11]  Shuji Hashimoto,et al.  Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese Population , 2016, Biological Psychiatry.

[12]  D. Söll,et al.  Crystal structures of the human elongation factor eEFSec suggest a non-canonical mechanism for selenocysteine incorporation , 2016, Nature Communications.

[13]  M. Daly,et al.  Erratum: Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia , 2016, Molecular Psychiatry.

[14]  M. Daly,et al.  Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia , 2016, Molecular Psychiatry.

[15]  Latarsha J. Carithers,et al.  The Genotype-Tissue Expression (GTEx) Project. , 2015, Biopreservation and biobanking.

[16]  R. Sturm,et al.  DCT protects human melanocytic cells from UVR and ROS damage and increases cell viability , 2014, Experimental dermatology.

[17]  Bulteau Anne-Laure,et al.  Selective up-regulation of human selenoproteins in response to oxidative stress. , 2014, Free radical biology & medicine.

[18]  M. Daly,et al.  Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles , 2014, Nature Communications.

[19]  V. Gladyshev,et al.  Selenoproteins: molecular pathways and physiological roles. , 2014, Physiological reviews.

[20]  L. Chavatte,et al.  Selective Up-regulation of Human Selenoproteins in Response to Oxidative Stress* , 2014, The Journal of Biological Chemistry.

[21]  E. Zeggini,et al.  Functional annotation of non-coding sequence variants , 2014, Nature Methods.

[22]  M. Hornig.  The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness , 2013, Current opinion in rheumatology.

[23]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[24]  Simon C. Potter,et al.  Mapping cis- and trans-regulatory effects across multiple tissues in twins , 2012, Nature Genetics.

[25]  T. Si,et al.  Use of Clozapine for the Treatment of Schizophrenia: Findings of the 2006 Research on the China Psychotropic Prescription Studies , 2012, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

[26]  K. Ravichandran.  Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. , 2011, Immunity.

[27]  W. Tate,et al.  Mutation in the TCRα subunit constant gene (TRAC) leads to a human immunodeficiency disorder characterized by a lack of TCRαβ+ T cells. , 2011, The Journal of clinical investigation.

[28]  S. Lowe,et al.  HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase , 2010, Nature.

[29]  David R. Jones,et al.  Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[30]  S. Cichon,et al.  New findings in the genetics of major psychoses , 2010, Dialogues in clinical neuroscience.

[31]  M. Lambert,et al.  Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors , 2008 .

[32]  M. McInnis,et al.  Psychiatric genetics: progress amid controversy , 2008, Nature Reviews Genetics.

[33]  E. Papoutsakis,et al.  Comparative analysis of transcriptional profiling of CD3+, CD4+ and CD8+ T cells identifies novel immune response players in T-Cell activation , 2008, BMC Genomics.

[34]  J. Uetrecht,et al.  Testing the hypothesis that vitamin C deficiency is a risk factor for clozapine-induced agranulocytosis using guinea pigs and ODS rats. , 2008, Chemical research in toxicology.

[35]  R. Flanagan,et al.  Haematological toxicity of drugs used in psychiatry , 2008, Human psychopharmacology.

[36]  J. Kane,et al.  Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia. , 2006, The Journal of clinical psychiatry.

[37]  M. Chopp,et al.  Dopachrome tautomerase (Dct) regulates neural progenitor cell proliferation. , 2006, Developmental biology.

[38]  Z. Husain,et al.  Increased FasL expression correlates with apoptotic changes in granulocytes cultured with oxidized clozapine. , 2006, Toxicology and applied pharmacology.

[39]  F. McMahon,et al.  G72/G30 in Schizophrenia and Bipolar Disorder: Review and Meta-analysis , 2006, Biological Psychiatry.

[40]  S. Leucht,et al.  Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. , 2006, The Journal of clinical psychiatry.

[41]  W. Honer,et al.  Linkage of familial schizophrenia to chromosome 13q32. , 1999, American journal of human genetics.

[42]  Abraham Weizman,et al.  HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. , 1998, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[43]  M. Pirmohamed,et al.  Mechanism of Clozapine-Induced Agranulocytosis , 1997, CNS drugs.

[44]  Dominic P. Williams,et al.  The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. , 1995, The Journal of pharmacology and experimental therapeutics.

[45]  V. Swope,et al.  Contribution of melanogenic proteins to the heterogeneous pigmentation of human melanocytes. , 1993, Journal of cell science.

[46]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[47]  H. Senn,et al.  CLOZAPINE AND AGRANULOCYTOSIS , 1977, The Lancet.

[48]  R. W. Griffith,et al.  CLOZAPINE AND AGRANULOCYTOSIS , 1975, The Lancet.

[49]  M. Olkinuora,et al.  CLOZAPINE AND AGRANULOCYTOSIS , 1975, The Lancet.

[50]  M. Lambert,et al.  Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors. , 2008, Expert opinion on pharmacotherapy.

[51]  P. Mitchell,et al.  Clozapine in China , 2008, Pharmacopsychiatry.

[52]  B. Blaine.  a review and meta-analysis , 2006 .

[53]  R. W. Griffith,et al.  Letter: Clozapine and agranulocytosis. , 1975, Lancet.